Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

A Correlation of Ineffective Erythropoiesis and Dysregulated Pathways in Myelodysplastic Syndromes

Junying Wu, Jinqin Liu, Lin Yang, Bing Li, Chen Jia, Fuhui Li, Robert Peter Gale, Zhi-jian Xiao

Blood (2024) 144 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2024-201427

Published: 2024

Journal Articles

Comparative Analysis of Patient Characteristics, Treatment Modalities, and Survival Outcomes in Chronic Lymphocytic Leukemia from China and the US

Yuting Yan, Yin Liu, Fan Yang, Jiamei Liu, Yanfei Chen, Ying Yu, Xiong Wenjie, Tingyu Wang, Zhijian Xiao, Jianxiang Wang, Thomas J. Kipps, Robert Peter Gale, Lu-Gui Qiu, Jifang Zhou, Shuhua Yi

Blood (2024) 144 (Supplement 1): 7820.

https://doi.org/10.1182/blood-2024-204512

Published: 2024

Journal Articles

Risks and Harms to Physicians Reporting Hematologic Adverse Drug Reactions (ADRs) to Health Authorities

Charles Bennett, Gretchen Watson, Kevin Knopf, Linda Martin, Robert Peter Gale

Blood (2024) 144 (Supplement 1): 7566.

https://doi.org/10.1182/blood-2024-208613

Published: 2024

Journal Articles

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Blood (2024) 144 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2024-207591

Published: 2024

Journal Articles

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Monia Marchetti, Alessandro Maria Vannucchi, John O. Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Robert Peter Gale, Claire Harrison, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Steffen Koschmieder, Ruben Mesa, Francesco Passamonti, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui

Blood (2024) 144 (Supplement 1): 7898.

https://doi.org/10.1182/blood-2024-198646

Published: 2024

Journal Articles

GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

Fuhui Li, Yudi Zhang, Chengwen Li, Qi Sun, Jinqin Liu, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Qingyan Gao, Meng Jiao, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6734.

https://doi.org/10.1182/blood-2024-200761

Published: 2024

Journal Articles

Impact of the 15-Item Frailty Scale in IPSS-R/IPSS-M Subgroup of Patients (Pts) with Myelodysplastic Syndromes (MDS)

Xin Wang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Bing Li, Li Juan Pan, Qingyan Gao, Meng Jiao, Jinying Zhao, Wenjun Xie, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6729.

https://doi.org/10.1182/blood-2024-199104

Published: 2024

Journal Articles

Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Blood (2024) 144 (Supplement 1): 3638.

https://doi.org/10.1182/blood-2024-206590

Published: 2024

Journal Articles

Factors Associated with Progression to Overt Acute Myeloid Leukemia in NPM1 -Mutated Myeloid Neoplasms with Less Than 10% Blasts

Jingye Gong, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Qingyan Gao, Meng Jiao, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2024-212110

Published: 2024

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Blood Basophil Concentration at Diagnosis Corelates with Prognosis in Newly-Diagnosed Persons with Chronic Myeloid Leukaemia

Lucia Vrablova, Xiaoshuai Zhang, Eva Kriegova, Milos Kudelka, Martin Radvansky, Sen Yang, Jaroslava Juranova, Tomas Papajik, Robert Peter Gale, Qian Jiang, Edgar Faber

Blood (2023) 142 (Supplement 1): 6374.

https://doi.org/10.1182/blood-2023-187548

Published: 2023

Journal Articles

FLT3-ITD Induces Immune Escape in AML Via up-Regulating CD47 Expression and Decreased Phagocytic Ability of Macrophages

Yun Wang, Shuzhao Chen, Limei Zhang, Jiangtao Song, Huaze Liao, Mayan Huang, Kunying Xie, Robert Peter Gale, Yang Liang

Blood (2023) 142 (Supplement 1): 2962.

https://doi.org/10.1182/blood-2023-190969

Published: 2023

Journal Articles

Single Cell Analyses Indicate SRSF2 and TET2 Co-Mutation Results in Skewed Haematopoiesis in Myelodysplastic Syndromes

Fang Hu, Xiaojin Li, Robert Peter Gale, Suning Chen, Yang Liang

Blood (2023) 142 (Supplement 1): 1848.

https://doi.org/10.1182/blood-2023-184508

Published: 2023

Journal Articles

3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2 nd Chronic Phase Able to Receive a Transplant

Mei Bao, Xiang Wang, Xiao-shuai Zhang, Zong-ru Li, Robert Peter Gale, Xiao-jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2023-185346

Published: 2023

Journal Articles

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms

Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Li Juan Pan, Robert Peter Gale, Bing Li, Zhijian Xiao

Blood (2023) 142 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2023-184604

Published: 2023

Journal Articles

Is the Prognosis of People with Chronic Myeloid Leukaemia Presenting in Accelerated Phase Always Worse Compared with People Presenting in Chronic Phase?

Sen Yang, Xiaoshuai Zhang, Mengyu Zhang, Robert Peter Gale, Xiao Jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2023-184568

Published: 2023

Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 9620–9623.

https://doi.org/10.1182/blood-2022-166431

Published: 2022

Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Blood (2022) 140 (Supplement 1): 9637–9639.

https://doi.org/10.1182/blood-2022-168703

Published: 2022

Journal Articles

Predicting Survival of Persons with Newly-Diagnosed Plasma Cell Myeloma

Limei Zhang, Yun Wang, Robert Peter Gale, Yang Liang

Blood (2022) 140 (Supplement 1): 10088–10089.

https://doi.org/10.1182/blood-2022-166634

Published: 2022

Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Blood (2022) 140 (Supplement 1): 3891–3894.

https://doi.org/10.1182/blood-2022-168812

Published: 2022

NARROW

A Correlation of Ineffective Erythropoiesis and Dysregulated Pathways in Myelodysplastic Syndromes

Comparative Analysis of Patient Characteristics, Treatment Modalities, and Survival Outcomes in Chronic Lymphocytic Leukemia from China and the US

Risks and Harms to Physicians Reporting Hematologic Adverse Drug Reactions (ADRs) to Health Authorities

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

Impact of the 15-Item Frailty Scale in IPSS-R/IPSS-M Subgroup of Patients (Pts) with Myelodysplastic Syndromes (MDS)

Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Factors Associated with Progression to Overt Acute Myeloid Leukemia in NPM1 -Mutated Myeloid Neoplasms with Less Than 10% Blasts

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood Basophil Concentration at Diagnosis Corelates with Prognosis in Newly-Diagnosed Persons with Chronic Myeloid Leukaemia

FLT3-ITD Induces Immune Escape in AML Via up-Regulating CD47 Expression and Decreased Phagocytic Ability of Macrophages

Single Cell Analyses Indicate SRSF2 and TET2 Co-Mutation Results in Skewed Haematopoiesis in Myelodysplastic Syndromes

3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2 nd Chronic Phase Able to Receive a Transplant

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms

Is the Prognosis of People with Chronic Myeloid Leukaemia Presenting in Accelerated Phase Always Worse Compared with People Presenting in Chronic Phase?

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Predicting Survival of Persons with Newly-Diagnosed Plasma Cell Myeloma

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only